Immuron Ltd has released a press release.
Trading halt
Filed with ASX ·
On 6ix: 6ix.com/news/trading-halt-904
6ix hasn’t read this filing yet.
Earlier from Immuron
- Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
- Immuron sales surge by 66% in the Third Quarter of FY19
- Immuron Aims to Secure FDA Approval for IMM-124E
- Company Update on CDI Clinical Trial and New Strategic Focus
- Travelan FY19 Update and Expansion into North America
Later from Immuron
- Preliminary Prospectus Supplement filed with SEC
- US DoD Reports Results from Travelan Shigellosis Study
- Immuron North American revenue surges by 52% in FY19
- Proposed Public Offer of IMRN ADSs
- Immuron Prices Underwritten Public Offering of ADSs
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron